Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE followed by FOLFOX-HAIC vs TACE alone in massive hepatocellular carcinoma
ChiCTR2500104648Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, folinic acid and fluorouracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500104648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104648.